Your browser doesn't support javascript.
The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis
Turkish Journal of Medical Sciences ; 52(3):547-553, 2022.
Article in English | CAB Abstracts | ID: covidwho-1935085
ABSTRACT
Background/

aim:

As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1 receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra in interventional groups compared to control/standard of care groups on mortality along with the provision of a prevalence estimate of the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS). Materials and

methods:

According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December 19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, anakinra, mortality, across the following databases PubMed/MEDLINE, Scopus, Web of Science, CINAHL Plus, and Cochrane. A random-effects model was applied using RevMan 5.4 for all statistical analyses.
Keywords

Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Type of study: Clinical Practice Guide / Prognostic study / Randomized controlled trials / Reviews / Risk factors Language: English Journal: Turkish Journal of Medical Sciences Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Type of study: Clinical Practice Guide / Prognostic study / Randomized controlled trials / Reviews / Risk factors Language: English Journal: Turkish Journal of Medical Sciences Year: 2022 Document Type: Article